2025年微创医疗站在新价值转折点,12月15日旗下心通医疗以约6.8亿美元估值“零现金”全资收购微创心律(CRM)。合并后微创心通收入将跃升至20亿元量级,进阶港股医疗器械板块前三。微创医疗早期“孵化+分拆”模式构建庞大版图,培育多家盈利上市公司,但行业进入深度调整期后,其从“分散播种”往“平台运营”跃迁。心脏病治疗复杂,心血管治疗“终极战场”是心力衰竭,CRM业务为微创心通注入经常性收入,后续...
Source Link2025年微创医疗站在新价值转折点,12月15日旗下心通医疗以约6.8亿美元估值“零现金”全资收购微创心律(CRM)。合并后微创心通收入将跃升至20亿元量级,进阶港股医疗器械板块前三。微创医疗早期“孵化+分拆”模式构建庞大版图,培育多家盈利上市公司,但行业进入深度调整期后,其从“分散播种”往“平台运营”跃迁。心脏病治疗复杂,心血管治疗“终极战场”是心力衰竭,CRM业务为微创心通注入经常性收入,后续...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.